Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

t Onyx Pharmaceuticals, Inc.  "This program is a highly innovative approach to industry-academia collaboration, bringing together leaders from the myeloma research community in the service of a common goal: driving an integrated, personalized approach to the development and delivery of medicines to patients."

Company-sponsored carfilzomib and oprozomib abstracts:

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib in Combination with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

  • Dr. James R. Berenson, Institute for Myeloma & Bone Cancer Research
  • Saturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  • Poster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  • Abstract # 1934

Association of Treatment Induced Peripheral Neuropathy (TIPN) with Treatment Patterns and Outcomes in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM)

  • Dr. Thomas Martin, University of California, San Francisco
  • Saturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  • Poster presentation: Health Services and Outcomes Research: Poster I
  • Abstract # 1750

Relationship of Serum Free Light Chain Reduction to Best Overall Response in Phase 2 Single-Agent and Combination Studies of Carfilzomib in Patients with Relapsed or Relapsed and/or Refractory Multiple Myeloma

  • Dr. Ravi Vij, Washington University School of Medicine, St. Louis, MO
  • Saturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  • Poster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  • Abstract # 1965

Clinical Profile of Single-Agent Modified-Rele
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... about IT project failure rates. Youve probably heard mention of ... poor requirements and scope definition, lack of business relevance or ... of this hand wringing is the real root cause. Its ... For each one, the source is the failure of specific ...
... Welcome to the global village called BIO 03. Lets ... , ,Starting at the Wisconsin Pavilion in the cavernous exhibit ... 100 the anniversary Harley-Davidson motorcycle parked in the corner. OK, ... its a great way to lure people into our aisle. ...
... Note: The Wisconsin Technology Council has published ... The 24-page publication highlights the states research base, ... contacts and the I-Q Corridor that joins Chicago, ... Technology Network has arranged to post excerpts from ...
Cached Biology Technology:Analog people in the digital revolution 2Analog people in the digital revolution 3On Location at BIO 2003 2Life Science: From the arts to the outdoors: Living and Playing in Wisconsin 2Life Science: From the arts to the outdoors: Living and Playing in Wisconsin 3Life Science: From the arts to the outdoors: Living and Playing in Wisconsin 4Life Science: From the arts to the outdoors: Living and Playing in Wisconsin 5
(Date:4/23/2014)... a newly coined term for novels and films which focus ... of Copenhagen shows how these fictions serve as a mental ... climate change and imagine other living conditions. , "Global ... the atmosphere; it is also a cultural phenomenon in which ... the films we see. And there are so many of ...
(Date:4/23/2014)... University of Exeter researcher has shed light on how ... in Australia,s remote outback have become reviled as pests ... of the Environment and Sustainability Institute at the University ... camel in Australia, from their historic role helping to ... as unwelcome "invader." , The deserts of the Australian ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3
... that allowing babies to swim is possibly not as ... till now," underlines Dr. Joachim Heinrich. He leads ... for Epidemiology. Prof. Dr. Dr. H. Erich ... This is a first indication. Nevertheless, it requires other ...
... receives funding from Hope Against Cancer (formerly The ... bilberries can prevent or delay the onset of ... University of Leicester, is leading an investigation ... produced substance Mirtoselect (extracted from bilberries), with the ...
... Mich. Scientists have identified and described stem cells specific ... master cells that give rise to the specialized cell types ... possible to pinpoint functioning stem cells in the stomach, either ... of University of Michigan Medical School researchers has succeeded in ...
Cached Biology News:Bilberry extract -- can it help prevent certain cancers? 2Bilberry extract -- can it help prevent certain cancers? 3Stomach stem cell discovery could bring cancer insights 2Stomach stem cell discovery could bring cancer insights 3
B2-Microgloulin...
... utilizies CTI Molecular Imaging's proprietary Focus™ detector ... volume as the R4. The microPET ... any commerically avaiable PET scanner. Focus ... of any scinitallor based PETsystems. The ...
...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: